SR-14968

SR-14968
Clinical data
Other names	SR14968
Drug class	μ-Opioid receptor biased agonist; Analgesic
Identifiers
	IUPAC name 3-[1-[1-(4-bromophenyl)ethyl]piperidin-4-yl]-5,6-dichloro-1H-benzimidazol-2-one;
CAS Number	2133455-40-8;
PubChem CID	130431386;
ChemSpider	95781537;
Chemical and physical data
Formula	C20H20BrCl2N3O
Molar mass	469.20 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C1=CC=C(C=C1)Br)N2CCC(CC2)N3C4=CC(=C(C=C4NC3=O)Cl)Cl;
	InChI InChI=1S/C20H20BrCl2N3O/c1-12(13-2-4-14(21)5-3-13)25-8-6-15(7-9-25)26-19-11-17(23)16(22)10-18(19)24-20(26)27/h2-5,10-12,15H,6-9H2,1H3,(H,24,27); Key:DJSSLECNUQMYKG-UHFFFAOYSA-N;

SR-14968 is a drug which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. It is closely related to other compounds such as SR-17018 although it is more potent and is a fully efficacious agonist. SR-14968 shows robust biased agonist activity in vitro, but in animal studies in vivo behaves more like a typical opioid agonist and will still produce respiratory suppression at higher doses although it has a wider safety profile compared to fentanyl. Compounds of this class are under development as potential analgesic medications with lower risk of overdose and drug dependence compared to traditional opioid drugs.^[1]^[2]^[3]^[4]^[5] SR-14968 was encountered online as a novel designer drug in 2025.^[6]